Psoriatic Arthritis News

Due to medical advancements, researchers are calling for an update to the U.S. Department of Defense’s policies restricting individuals with psoriasis and atopic dermatitis from joining and remaining in the military, according to a study.

Difficult-to-treat psoriatic arthritis was common in a large, real-life cohort, with key risk factors including extensive psoriasis, higher BMI and a history of inflammatory bowel disease, according to data published in Rheumatology.

The ability to view laboratory results, track symptoms and sharing them with a provider were rated as the most useful potential app functions by patients with rheumatic and musculoskeletal diseases, according to data.

Serious infections were uncommon among patients with psoriatic arthritis exposed to targeted therapies for the first time in “a large and exhaustive” French cohort, according to data published in RMD Open.

CLEVELAND — Dermatology and rheumatology often work together in the treatment of psoriasis and psoriatic arthritis.

The FDA has expanded the indication of Rinvoq to include active, polyarticular juvenile idiopathic arthritis and psoriatic arthritis in children aged 2 years and older, according to an AbbVie press release.

Patients with rheumatic diseases demonstrate a high reliance on opioids around the time of diagnosis, and significant numbers of patients were not on appropriate treatment in the year afterward, according to data in Clinical Rheumatology.

CLEVELAND — With myriad treatment options now available for psoriasis vulgaris, recent research is focusing on reaching higher goals, Anthony P. Fernandez, MD, PhD, said at the Medical Dermatology Therapy Update III meeting.

Although TNF inhibitors remain the first choice biologic for many rheumatologists treating psoriatic arthritis, interleukin-17 inhibitors may soon overtake them, according to a market analysis from Spherix Global Insights.

Simlandi injection, an interchangeable biosimilar to Humira, is now available in the U.S. for the treatment of psoriatic arthritis, plaque psoriasis and other conditions, Teva Pharmaceuticals and Alvotech announced in a press release.